Search Results
You are looking at 1 - 6 of 6 items for
- Author: Francesca Spada x
- Refine by access: All content x
Search for other papers by Vito Amoroso in
Google Scholar
PubMed
Search for other papers by Giorgio Maria Agazzi in
Google Scholar
PubMed
Search for other papers by Elisa Roca in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Alessandra Mosca in
Google Scholar
PubMed
Search for other papers by Marco Ravanelli in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Roberto Maroldi in
Google Scholar
PubMed
Search for other papers by Alfredo Berruti in
Google Scholar
PubMed
Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Metal Targeted Therapy & Immunology lab, Childrens’ cancer institute, Sydney, NSW, Australia
Search for other papers by Riccardo Cazzoli in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Giuseppina De Petro in
Google Scholar
PubMed
Search for other papers by Germano Gaudenzi in
Google Scholar
PubMed
Search for other papers by Silvia Carra in
Google Scholar
PubMed
Search for other papers by Mauro Romanenghi in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Ilaria Grossi in
Google Scholar
PubMed
Search for other papers by Isabella Pallavicini in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Search for other papers by Saverio Minucci in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vitro and in vivo models. For cell cultures, we used BON-1, NCI-H727 and NCI-H720 cell lines. Cell viability was assessed by manual count coupled with quantification of cell death, performed through fluorescence-activated cell sorting analysis as propidium iodide exclusion assay. In addition, we investigated the modulation of the antiapoptotic myeloid cell leukemia 1 protein under CAB exposure, as a putative adaptive pro-survival mechanism, and compared the responses with sunitinib. The activity of CAB was also tested in mouse and zebrafish xenograft tumor models. Cabozantinib showed a dose-dependent and time-dependent effect on cell viability and proliferation in human NET cultures, besides a halting of cell cycle progression for endoduplication, never reported for other tyrosine kinase inhibitors. In a transplantable zebrafish model, CAB drastically inhibited NET-induced angiogenesis and migration of implanted cells through the embryo body. CAB showed encouraging activity in NETs, both in vitro and in vivo models. On this basis, we envisage future research to further investigate along these promising lines.
Department of Biotechnological and Applied Clinical Sciences, Department of Neurological Sciences, Endocrinology, CNRS, AP‐HM, Endocrinology and Diabetology Unit, Endocrinology, Department of Neurology and Psychiatry, INSERM, AP‐HM, Department of Radiology, University of L'Aquila, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Search for other papers by Marie-Lise Jaffrain-Rea in
Google Scholar
PubMed
Search for other papers by Sandra Rotondi in
Google Scholar
PubMed
Search for other papers by Annarita Turchi in
Google Scholar
PubMed
Search for other papers by Gianluca Occhi in
Google Scholar
PubMed
Department of Biotechnological and Applied Clinical Sciences, Department of Neurological Sciences, Endocrinology, CNRS, AP‐HM, Endocrinology and Diabetology Unit, Endocrinology, Department of Neurology and Psychiatry, INSERM, AP‐HM, Department of Radiology, University of L'Aquila, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Search for other papers by Anne Barlier in
Google Scholar
PubMed
Search for other papers by Erika Peverelli in
Google Scholar
PubMed
Search for other papers by Lilya Rostomyan in
Google Scholar
PubMed
Search for other papers by Céline Defilles in
Google Scholar
PubMed
Search for other papers by Mariolina Angelini in
Google Scholar
PubMed
Search for other papers by Maria-Antonietta Oliva in
Google Scholar
PubMed
Search for other papers by Filippo Ceccato in
Google Scholar
PubMed
Search for other papers by Orlando Maiorani in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Department of Biotechnological and Applied Clinical Sciences, Department of Neurological Sciences, Endocrinology, CNRS, AP‐HM, Endocrinology and Diabetology Unit, Endocrinology, Department of Neurology and Psychiatry, INSERM, AP‐HM, Department of Radiology, University of L'Aquila, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Search for other papers by Vincenzo Esposito in
Google Scholar
PubMed
Search for other papers by Francesca Buttarelli in
Google Scholar
PubMed
Department of Biotechnological and Applied Clinical Sciences, Department of Neurological Sciences, Endocrinology, CNRS, AP‐HM, Endocrinology and Diabetology Unit, Endocrinology, Department of Neurology and Psychiatry, INSERM, AP‐HM, Department of Radiology, University of L'Aquila, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Search for other papers by Dominique Figarella-Branger in
Google Scholar
PubMed
Department of Biotechnological and Applied Clinical Sciences, Department of Neurological Sciences, Endocrinology, CNRS, AP‐HM, Endocrinology and Diabetology Unit, Endocrinology, Department of Neurology and Psychiatry, INSERM, AP‐HM, Department of Radiology, University of L'Aquila, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Search for other papers by Felice Giangaspero in
Google Scholar
PubMed
Search for other papers by Anna Spada in
Google Scholar
PubMed
Search for other papers by Carla Scaroni in
Google Scholar
PubMed
Search for other papers by Edoardo Alesse in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Germline aryl hydrocarbon receptor interacting protein (AIP) gene mutations confer a predisposition to pituitary adenoma (PA), predominantly GH-secreting (GH-PA). As recent data suggest a role for AIP in the pathogenesis of sporadic GH-PA and their response to somatostatin analogues (SSA), the expression of AIP and its partner, aryl hydrocarbon receptor (AHR), was determined by semiquantitative immunohistochemistry scoring in 62 sporadic GH-PA (37 treated with SSA preoperatively). The influence of Gsp status was studied in a subset of tumours (n=39, 14 Gsp +) and six GH-PA were available for primary cultures. AIP and AHR were detected in most cases, with a positive correlation between AIP and cytoplasmic AHR (P=0.012). Low AIP expression was significantly more frequent in untreated vs SSA-treated tumours (44.0 vs 20.5%, P=0.016). AHR expression or localisation did not differ between the two groups. Similarly, in vitro octreotide induced a median twofold increase in AIP expression (range 1.2–13.9, P=0.027) in GH-PA. In SSA-treated tumours, the AIP score was significantly higher in the presence of preoperative IGF1 decrease or tumour shrinkage (P=0.008 and P=0.014 respectively). In untreated tumours, low AIP expression was significantly associated with invasiveness (P=0.028) and suprasellar extension (P=0.019). The only effect of Gsp status was a significantly lower nuclear AHR score in Gsp + vs Gsp − tumours (P=0.025), irrespective of SSA. In conclusion, AIP is involved in the aggressiveness of sporadic GH-PA, regardless of Gsp status, and AIP up-regulation in SSA-treated tumours is associated with a better preoperative response, with no clear role for AHR.
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Carmine Valenza in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Francesco Multinu in
Google Scholar
PubMed
Search for other papers by Lavinia Benini in
Google Scholar
PubMed
Search for other papers by Michele Borghesani in
Google Scholar
PubMed
Search for other papers by Laura Algeri in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Search for other papers by Silvestro Carinelli in
Google Scholar
PubMed
Search for other papers by Simone Bruni in
Google Scholar
PubMed
Search for other papers by Gabriella Schivardi in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Giuseppe Curigliano in
Google Scholar
PubMed
Search for other papers by Vanna Zanagnolo in
Google Scholar
PubMed
Division of Gynecologic Surgery, European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy
Search for other papers by Giovanni Aletti in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Search for other papers by Nicoletta Colombo in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy and discussed at the European Institute of Oncology’s Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient.
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Francesco Barretta in
Google Scholar
PubMed
Search for other papers by Annalisa Trama in
Google Scholar
PubMed
Search for other papers by Laura Botta in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Roberto Buzzoni in
Google Scholar
PubMed
University of Milan, Milan, Italy
Search for other papers by Filippo De Braud in
Google Scholar
PubMed
Liver Surgery, Transplantation and Gastroenterology, University of Milan and Istituto Nazionale Tumori Fondazione IRCCS, ENETS Center of Excellence, Milano, Milan, Italy
Search for other papers by Vincenzo Mazzaferro in
Google Scholar
PubMed
Search for other papers by Ugo Pastorino in
Google Scholar
PubMed
Search for other papers by Ettore Seregni in
Google Scholar
PubMed
Search for other papers by Luigi Mariani in
Google Scholar
PubMed
Search for other papers by Gemma Gatta in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Daniela Femia in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Francesco Panzuto in
Google Scholar
PubMed
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Maria Pia Brizzi in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Laura Catena in
Google Scholar
PubMed
Search for other papers by Harry Comber in
Google Scholar
PubMed
Search for other papers by Fiona Dwane in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Dario Giuffrida in
Google Scholar
PubMed
Search for other papers by Kris Henau in
Google Scholar
PubMed
Search for other papers by Toni Ibrahim in
Google Scholar
PubMed
Search for other papers by Riccardo Marconcini in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Maja Primic Žakelj in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Elizabeth Van Eycken in
Google Scholar
PubMed
Search for other papers by Jan Maaten Van der Zwan in
Google Scholar
PubMed
Search for other papers by Tina Žagar in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Rosalba Miceli in
Google Scholar
PubMed
Search for other papers by NEPscore Working Group in
Google Scholar
PubMed
No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three ‘field-practice’ cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Molecular Medicine Program, University of Pavia, Pavia, Italy
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Mohamad Sonbol in
Google Scholar
PubMed
Search for other papers by Rachel A Eiring in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Benedetta Lombardi Stocchetti in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by David J Gross in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Patrick Robelin in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Samuele Frassoni in
Google Scholar
PubMed
Search for other papers by Vincenzo Bagnardi in
Google Scholar
PubMed
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Clotilde Sparano in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Fabio Gelsomino in
Google Scholar
PubMed
Search for other papers by Alberto Bongiovanni in
Google Scholar
PubMed
Search for other papers by Nicoletta Ranallo in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Maura Rossi in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Ibrahim Rasul Kakil in
Google Scholar
PubMed
Search for other papers by Hytam Hamid in
Google Scholar
PubMed
Search for other papers by Alessandra Chirco in
Google Scholar
PubMed
Search for other papers by Michela Squadroni in
Google Scholar
PubMed
Search for other papers by Anna La Salvia in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Sabrina Boselli in
Google Scholar
PubMed
Search for other papers by Darina Tamayo in
Google Scholar
PubMed
Search for other papers by Cristina Mazzon in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.